US Senate Panel Passes Breakthrough Device Pathway And Other Measures
This article was originally published in SRA
The US Senate Health, Education, Labor and Pensions Committee has passed breakthrough medical device legislation, as well as combination products and digital health regulatory reform bills, as part of the panel's effort to pass a broad-reaching biomedical innovation package this year1.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.